U.S. markets open in 5 hours 53 minutes

Aurinia Pharmaceuticals Inc. (AUPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.64-0.22 (-1.71%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close12.86
Open12.87
Bid0.00 x 900
Ask0.00 x 1400
Day's Range12.54 - 12.94
52 Week Range9.72 - 20.50
Volume1,644,361
Avg. Volume3,647,555
Market Cap1.626B
Beta (5Y Monthly)0.36
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Aurinia's Lupkynis Shows Sustained Renal Response Rates In Lupus Nephritis Patients
    Benzinga

    Aurinia's Lupkynis Shows Sustained Renal Response Rates In Lupus Nephritis Patients

    Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has announced a supportive interim analysis of its AURORA 2 continuation study evaluating Lupkynis (voclosporin) in lupus nephritis. Data will be presented at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2021 Congress in June. Subjects who completed one year of treatment in Aurinia's Phase 3 AURORA 1 study were eligible to enroll in the continuation study (AURORA 2). The interim analysis of AURORA 2 showed that subjects in the Lupkynis treatment arm sustained meaningful reductions in proteinuria, with no change in mean estimated glomerular filtration rate (eGFR) at 104 weeks of treatment. Proteinuria continued to improve with a greater reduction in UPCR from pre-treatment baseline to year two observed in the voclosporin arm compared to the control arm (-3.1 vs. -2.1 mg/mg). A greater reduction in proteinuria between arms was observed between 1 and 2 years (1.0 vs. 0.6 mg/mg; voclosporin vs. control). Renal function as determined by eGFR remained stable over 104 weeks in both groups compared to baseline assessments. Mean eGFR: 79.6 vs 79.0 mL/min for the voclosporin arm and 78.9 vs 82.9 mL/min for the control arm. Additionally, there were no unexpected new adverse events observed. Price Action: AUPH shares closed at $12.82 on Thursday. See more from BenzingaClick here for options trades from BenzingaAurinia Pharma's Stock Gains After Lupkynis Data From Late-Stage Lupus Nephritis Study Published In Lancet© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • 2 Grossly Undervalued Biotech Stocks That Could Double Your Money
    Motley Fool

    2 Grossly Undervalued Biotech Stocks That Could Double Your Money

    Biotech stocks are officially in a slump. The industry has suddenly lost favor with investors because of a confluence of headwinds, including an apparently stricter Food and Drug Administration (FDA), the politics of the never-ending drug pricing debate, and the specter of rising interest rates and higher capital gains taxes. Seasoned biotech investors, though, know that downturns in the space are typically an outstanding buying opportunity.

  • Is the Options Market Predicting a Spike in Aurinia (AUPH) Stock?
    Zacks

    Is the Options Market Predicting a Spike in Aurinia (AUPH) Stock?

    Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.